HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through personalized insights, ...

Unlike any single-lead or 6-lead consumer device, HeartBeam’s patented cable-free technology captures the heart’s electrical signals in three non-coplanar dimensions and synthesizes them into a ...

Milestone Pharmaceuticals announced the FDA approval of prescription etripamil nasal spray for the treatment of acute ...

Secures FDA 510(K) Clearance For 12-Lead ECG Synthesis Software Following Successful Appeal. HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through ...

With the paid subscription, you also get additional benefits such as cloud storage, blood pressure monitoring, medication ...

Young adults face rising cardiac arrest risks due to stress, sleep issues, and unhealthy habits. Regular exercise and early ...

Heart disease often develops silently for years before striking without warning. But this scan offers a powerful way to ...

Heart disease continues to claim the most lives in the Philippines, yet many Filipinos only think about their hearts when ...

A hidden atrial dysfunction may raise stroke risk in people with transthyretin amyloid cardiomyopathy (ATTR-CM); however, a ...

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly ...

The FDA has approved intranasal etripamil (Cardamyst; Milestone Pharmaceuticals) for the acute treatment of paroxysmal supraventricular tachycardia (PSVT), making it the first self-administered, ...

A man in his 50s, normally fit and well, had an ischaemic thalamic stroke confirmed on MRI, manifesting with left-sided weakness, numbness and ataxia. Admission BP was 254/150 mm Hg. All tests for ...